Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)
During the Trading Day
| 2.26 |  +0.05 / +2.26% |
Data as of 3:59pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 2.30 | +0.04 / +1.77% |
Volume: 23.2K |
Latest LXRX News | Press Releases
No recent news for Lexicon Pharmaceuticals Inc.
Today’s Trading
| Previous close | 2.21 |
| Today’s open | 2.21 |
| Day’s range | 2.15 - 2.28 |
| Volume | 837,194 |
| Average volume (3 months) | 859,157 |
| Market cap | $1.1B |
| Dividend yield | -- |
Data as of 3:59pm ET, 06/18/2013
Growth & Valuation
| Earnings growth (last year) | +32.35% |
| Earnings growth (this year) | +10.87% |
| Earnings growth (next 5 years) | +42.00% |
| Revenue growth (last year) | -41.10% |
| P/E ratio | NM |
| Price/Sales | 993.80 |
| Price/Book | 4.24 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NKTRNektar Therapeutics | +0.48 | +5.14% |
| AMRNAmarin Corporation P... | -0.02 | -0.30% |
| EXELExelixis Inc | +0.15 | +3.21% |
| NXTMNxstage Medical Inc | +0.19 | +1.33% |
Data as of 4:00pm ET, 06/18/2013
Financials
| Next reporting date | July 30, 2013 |
| EPS forecast (this quarter) | -$0.05 |
| Annual revenue (last year) | $1.1M |
| Annual profit (last year) | -$110.2M |
| Net profit margin | -10,120.39% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Arthur T. Sands, MD, PhD |
Vice President-Finance & Accounting James F. Tessmer, MBA, CPA |
Corporate headquarters The Woodlands, Texas |
Forecasts
